Buy Medications no RX

GPs are more likely to prescribe headache drugs to middle-aged women than men, a study has claimed. Researchers at King's College London found women aged between 45 and 54 were three times as likely to visit their GP about headaches while men were more likely to be referred to hospital. Read more…

Belgian firm Solvay has released its results for 2005 with pharmaceutical sales up 30 per cent to 2.27 billion euros. The company as a whole had profits of 816 million euros for the year. Read more…

AstraZeneca has lodged its appeal over losing the patent for hypertension treatment Toprol XL (metoprolol succinate). In January US court ruled that two patents for the extended release tablet were invalid and unenforceable finding in favour of the defendants KV Pharmaceutical, Andrx Corp and Novartis's Eon Labs. Read more…

Women can safely have DIY abortions at home, a study has concluded. The pilot study, set up by the Department of Health (DoH), found that women less than nine weeks pregnant could safely have the medical abortion outside of hospital. Read more…

The Medicines and Healthcare products Regulatory Agency (MHRA) has forced Eli Lilly to withdraw an advice leaflet. The leaflet, providing doctors with advice on treatments for mental health, was written on behalf of Diabetes UK and carried the logo of the charity, reports the Financial Times. Read more…

Sanofi-Aventis has recalled 30 batches of the anticoagulant Clexane (enoxaparin). The move was made after quality control tests found there was the possibility that there could be an over-concentration of the active ingredient in a limited number of syringes. Read more…

The US Food and Drug Administration (FDA) has begun its review of GlaxoSmithKline's (GSK) investigational antibacterial retapamulin. GSK submitted a new drug application (NDA) for retapamulin in November last year and expects to receive approval later this year. Read more…

Eli Lilly is to buy back worldwide marketing rights for Yentreve/AriClaim (duloxetine hydrochloride) from Boehringer Ingelheim. As a stress urinary incontinence (SUI) treatment, along with future related urinary incontinence indications, the drug will continue to be marketed outside the US by Lilly but other treatments using duloxetine will remain under both firms. Read more…

A woman suffering from early-stage breast cancer has lost a legal battle to force her health authority to treat her with Herceptin. High court judge Mr Justice Bean ruled this morning that that Swindon primary care trust (PCT) in Wiltshire did not need to pay for Ann Marie Rogers, 54, to be treated with the drug, which can cost up to ?20,000 for one year of treatment. Read more…

Botox could be used alongside chemotherapy and radiation to fight cancer, new research has suggested. The cosmetic treatment produced by Allergan, which is normally used to smooth wrinkles, was found to destroy resistant cancer cells in tests on mice. Read more…

Health secretary Patricia Hewitt yesterday announced details of an allocation of over ?2 billion worth of capital investment in health services over the next financial year. Capital funding is used to acquire and modernise buildings, land and equipment within the NHS and can only be used to fund these aspects. Read more…

Forest Laboratories has decided to up figures for research and development (R&D) spending. The move comes as a way to include new agreements with US firms Mylan Laboratories and Replidyne. Read more…

Pliva is to buy a Spanish subsidiary from Novartis' generics division Sandoz. The Croatian firm will pay 21.5 million euros for Uso Racional (UR), a well known and established generic brand in Spain with expected sales of 12 million euros for 2006. Read more…

Studies of the GlaxoSmithKline (GSK) drug Arixtra (fondaparinux sodium) have found it to be effective. Artemis (Arixtra for Thromboembolism prevention in a Medical Indications Study) found the treatment reduced the risk of venous thromboembolism (VTE) by 46.7 per cent. Read more…

AstraZeneca is to withdraw the anticoagulant Exanta (melagatran/ximelagatran) from the market and end its development. The venous thromboembolism (VTE) treatment has been withdrawn due to new data about the possibility of liver damage. Read more…

Cephalon has reported an increase of revenue for 2005 of 19 per cent to $1.2 billion. The firm's total sales hit $1.16 billion, a rise of 18 per cent on 2004 levels, with the biggest seller being the narcolepsy drug Provigil (modafinil) with sales of $512.8 million. However, despite these figures the company made a loss for the year of $175 million, compared with a loss of $74 million in 2004. Read more…

The Scottish Medicines Consortium (SMC) has given its approval of Bonviva (ibandronic acid) for the use within NHS Scotland for the treatment of osteoporosis. The body stated that the once a month treatment was found "to significantly reduce the risk of vertebral fractures in postmenopausal women". Read more…

MPs have voted to extend a smoking ban in public places to all pubs and private clubs in England. The free vote in the House of Commons went 384 to 184 in the government's favour last night to remove the exemption of private members' clubs and establishments that serve food. MPs also voted to ban smoking in workplaces, including 106,000 licensed premises. Read more…

Physicians and patients should carefully weigh the risks of ESAs against transfusion risks. Read more…

New study indicates that targeting p73 in mice induces the regression of established tumors of human origin. Read more…

The U.S. District Court for the Southern District of New York issued an opinion to explain, elaborate and refine its determinations regarding the exclusion of and admissibility of 'generic' expert testimony in litigation involving personal injury or wrongful death caused by dietary supplements containing Ephedra. The litigation is In re Ephedra Prod. Liab. Litig. (No. 04-1598 S.D.N.Y.) Read more…

A New Jersey State jury allowed a major victory for Merck & Co. in one of many court battles they are fighting over their Vioxx painkiller. Read more…

Celebrex is used to relieve symptoms of osteoarthritis (the arthritis caused by age-related 'wear and tear' on bones and joints) as well as relieve symptoms of rheumatoid arthritis in adults. Read more…

According to an internal company document, even as Merck & Co. was publicly playing down a study that highlighted the pain reliever Vioxx's potential heart attack risk, company researchers privately sought to reformulate Vioxx in 2000 to reduce its cardiovascular side effects. Read more…

An Alabama state court judge has ordered Vioxx manufacturer Merck & Co. to begin settlement talks with the widow of an Alabama man who blames the pain medication for her husband's death. Read more…